CA2367820C - Nmr-method for determining the risk of developing type 2 diabetes - Google Patents

Nmr-method for determining the risk of developing type 2 diabetes Download PDF

Info

Publication number
CA2367820C
CA2367820C CA002367820A CA2367820A CA2367820C CA 2367820 C CA2367820 C CA 2367820C CA 002367820 A CA002367820 A CA 002367820A CA 2367820 A CA2367820 A CA 2367820A CA 2367820 C CA2367820 C CA 2367820C
Authority
CA
Canada
Prior art keywords
glucose
nmr
patient
lipoprotein
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002367820A
Other languages
English (en)
French (fr)
Other versions
CA2367820A1 (en
Inventor
James D. Otvos
Dennis W. Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Liposcience Inc
Original Assignee
North Carolina State University
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, Liposcience Inc filed Critical North Carolina State University
Publication of CA2367820A1 publication Critical patent/CA2367820A1/en
Application granted granted Critical
Publication of CA2367820C publication Critical patent/CA2367820C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002367820A 1999-04-22 2000-04-19 Nmr-method for determining the risk of developing type 2 diabetes Expired - Fee Related CA2367820C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13061299P 1999-04-22 1999-04-22
US60/130,612 1999-04-22
PCT/US2000/010463 WO2000065366A1 (en) 1999-04-22 2000-04-19 Nmr-method for determining the risk of developing type 2 diabetes

Publications (2)

Publication Number Publication Date
CA2367820A1 CA2367820A1 (en) 2000-11-02
CA2367820C true CA2367820C (en) 2009-12-22

Family

ID=22445506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002367820A Expired - Fee Related CA2367820C (en) 1999-04-22 2000-04-19 Nmr-method for determining the risk of developing type 2 diabetes

Country Status (9)

Country Link
US (1) US6518069B1 (US06573293-20030603-C00009.png)
EP (1) EP1171778B1 (US06573293-20030603-C00009.png)
JP (1) JP4585693B2 (US06573293-20030603-C00009.png)
AT (1) ATE319105T1 (US06573293-20030603-C00009.png)
AU (1) AU4469300A (US06573293-20030603-C00009.png)
CA (1) CA2367820C (US06573293-20030603-C00009.png)
DE (1) DE60026287T2 (US06573293-20030603-C00009.png)
ES (1) ES2256000T3 (US06573293-20030603-C00009.png)
WO (1) WO2000065366A1 (US06573293-20030603-C00009.png)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7395158B2 (en) * 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
US20040236673A1 (en) * 2000-10-17 2004-11-25 Eder Jeff Scott Collaborative risk transfer system
CA2331116A1 (en) 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
US20050130321A1 (en) 2001-04-23 2005-06-16 Nicholson Jeremy K. Methods for analysis of spectral data and their applications
EP1384073A2 (en) * 2001-04-23 2004-01-28 Metabometrix Limited Methods for analysis of spectral data and their applications: osteoporosis
US20040162678A1 (en) * 2001-08-13 2004-08-19 Donald Hetzel Method of screening for disorders of glucose metabolism
ATE525635T1 (de) * 2001-11-13 2011-10-15 Univ California Ionenmobilitätsanalyse biologischer partikel
US6873914B2 (en) 2001-11-21 2005-03-29 Icoria, Inc. Methods and systems for analyzing complex biological systems
US6862592B1 (en) * 2001-12-21 2005-03-01 Adobe Systems Incorporated Document processing in a cross-platform environment
EP1329716A1 (en) * 2002-01-16 2003-07-23 Roche Diagnostics GmbH Method for screening biological samples for presence of the metabolic syndrome
US7730063B2 (en) * 2002-12-10 2010-06-01 Asset Trust, Inc. Personalized medicine service
US20080027769A1 (en) * 2002-09-09 2008-01-31 Jeff Scott Eder Knowledge based performance management system
US7426499B2 (en) * 2004-11-08 2008-09-16 Asset Trust, Inc. Search ranking system
US20070011049A1 (en) * 2005-07-09 2007-01-11 Eder Jeffrey S Intelligent, personalized commerce chain
WO2004040407A2 (en) * 2002-10-25 2004-05-13 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
DE10315877B4 (de) 2003-04-08 2005-11-17 Roche Diagnostics Gmbh Krankheitsverlaufkontrolle
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) * 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US7197427B2 (en) * 2004-03-31 2007-03-27 Genworth Financial Inc. Method for risk based testing
JP5248854B2 (ja) * 2004-04-01 2013-07-31 リポサイエンス，インコーポレイテッド 臨床ｎｍｒ体外診断解析器の作動方法及び臨床ｎｍｒ体外診断解析器
US7422224B2 (en) * 2004-04-13 2008-09-09 Kimir Seatpost Adjustable bicycle seat post assembly
US20060010098A1 (en) 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
US7951078B2 (en) * 2005-02-03 2011-05-31 Maren Theresa Scheuner Method and apparatus for determining familial risk of disease
DE502006001913D1 (de) 2005-03-15 2008-12-11 Roche Diagnostics Gmbh Verfahren und System zur Untersuchung des Glucosestoffwechsels
WO2007110358A2 (en) * 2006-03-24 2007-10-04 Metanomics Gmbh Means and method for predicting diabetes
US8498915B2 (en) * 2006-04-02 2013-07-30 Asset Reliance, Inc. Data processing framework for financial services
US8247235B2 (en) 2007-06-08 2012-08-21 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US9354200B1 (en) 2008-08-07 2016-05-31 Quest Diagnostics Investments Incorporated Detection apparatus for differential-charged particle mobility analyzer
EP2344890B1 (en) * 2008-10-20 2021-08-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods
DE102009026651A1 (de) 2009-06-02 2011-02-17 Großmann, Kay, Dr. rer. nat. (Chemie) Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten
US9250211B2 (en) 2010-12-30 2016-02-02 Quest Diagnostics Investments Incorporated Magnetic separation of lipoproteins using dextran sulfate
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
WO2012163361A1 (en) * 2011-05-31 2012-12-06 Aarhus Universitet Method and system for identification of physiological imbalance in an animal
US9689942B2 (en) 2011-06-30 2017-06-27 Liposcience, Inc. Quantitative NMR clinical analyzers with automatic NMR temperature sensitivity compensation that accommodate large ambient operational temperature ranges
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
DE102014203721B4 (de) * 2014-02-28 2018-12-27 Bruker Biospin Gmbh Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe
CA2965172A1 (en) 2014-10-21 2016-04-28 Philip Guadagno Quantitative molar concentration detection of specific apolipoprotein-containing particles present in bodily fluids by using capillary electrophoresis
EP3210028A1 (en) 2014-10-21 2017-08-30 True Health IP LLC Lipoprotein particle number from measurements of lipoprotein particle phospholipid concentration in lipoprotein particle membrane bilayer
CA2965675A1 (en) 2014-10-27 2016-05-06 True Health Ip Llc Lp(a) subform size identification by capillary isotachophoresis electrophoresis with laser-induced-fluorescence
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
US11156621B2 (en) * 2017-09-07 2021-10-26 Liposcience, Inc. Multi-parameter metabolic vulnerability index evaluations
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health
WO2023239869A1 (en) * 2022-06-09 2023-12-14 Quest Diagnostics Investments Llc Quantification of lipoprotein subfractions by ion mobility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4933844A (en) * 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
BR9007936A (pt) 1989-12-21 1992-10-27 Beth Israel Hospital Processo para diagnosticar risco arterioscleroso,e processo de medicao de concentracoes de lipoproteina
WO1993003450A1 (en) 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
US5585235A (en) * 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
NZ275054A (en) * 1993-11-08 1997-04-24 Peptide Delivery Systems Pty L Diagnosing atherosclerosis or coronary artery disease using labelled composition which mimics essential features of an exogenous lipoprotein
US5685300A (en) * 1994-04-01 1997-11-11 Kuenstner; J. Todd Noninvasive and in-vitro measurement of glucose and cholesterol by nuclear magnetic resonance spectroscopy
US6163154A (en) 1997-12-23 2000-12-19 Magnetic Diagnostics, Inc. Small scale NMR spectroscopic apparatus and method
US6226082B1 (en) 1998-06-25 2001-05-01 Amira Medical Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy

Also Published As

Publication number Publication date
US6518069B1 (en) 2003-02-11
WO2000065366A8 (en) 2001-03-29
JP4585693B2 (ja) 2010-11-24
JP2002543392A (ja) 2002-12-17
EP1171778B1 (en) 2006-03-01
AU4469300A (en) 2000-11-10
EP1171778A1 (en) 2002-01-16
ES2256000T3 (es) 2006-07-16
DE60026287T2 (de) 2006-08-17
CA2367820A1 (en) 2000-11-02
DE60026287D1 (de) 2006-04-27
WO2000065366A1 (en) 2000-11-02
ATE319105T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
CA2367820C (en) Nmr-method for determining the risk of developing type 2 diabetes
Ala-Korpela Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics
US8386187B2 (en) Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
US20180372716A1 (en) Diagnosing multiple sclerosis
CN104350384B (zh) Pc‑o 44:4－一种用于内脏脂肪过多的生物标志物
CN110853719B (zh) 神经酰胺三己糖苷d18:0/24:1作为生物标志物在诊断阿尔茨海默病中的应用
Kardia et al. Correlates of family history of coronary artery disease in children
WO2004044602A1 (en) Detection of demyelination
US20060210476A1 (en) Metabonomics homogeneity analysis
Christenson et al. A-009 Analytical Characterization of a Novel NT-proBNP Assay on a Central Laboratory Platform
US20120108947A1 (en) Method for predicting weight gain associated with a pharmaceutical therapy
Berman et al. A-119 Lipemia Interference
Berman et al. A-118 Sigma Metric Performance of Chemistry Assays on 4 Instrument Systems
Okunieff et al. Failure of 1H nuclear magnetic resonance spectroscopy of blood plasma to detect malignancy.
RU2252417C1 (ru) Способ диагностики артериальной гипертонии у лиц молодого возраста
Aktuğlu et al. Akut Koroner Sendromun Erken Tanısında Kalp Tipi Serbest Yağ Asidi Bağlayıcı Proteinin, CPK-MB ve Troponin-I’in karşılaştırılması
Wiebe Lipid testing for the year 2000 and beyond
Matter AXINON® lipoFIT®
Stein Use of the Clinical Laboratory for Lipid Evaluation
Ion-Margineanu et al. Classifying Multiple Sclerosis courses by combining clinical data with Magnetic Resonance metabolic features and lesion loads

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180419